Pfizer CEO Albert Bourla
Sakis Mitrolidis/AFP via Getty Images
were upgraded to Buy from Neutral at UBS, with the firm writing that it expects antiviral pill Paxlovid to reach sales of at least $14 billion next year, or 40% above Wall Street expectations.
UBS analyst Colin Bristow, in a research note Monday, also boosted the price target on the stock to $60 from $52.
Pfizer (ticker: PFE) shares rose 2.5% to $54.10. The company announced Monday it was acquiring
for $100 a share, or $6.7 billion.
The rating from UBS was issued before the acquisition was announced.
Bristow wrote how Pfizer’s Covid franchise — Paxlovid and Cominarty, the company’s Covid-19 vaccine — has peak sales potential in 2022 of $50 billion.
UBS estimates that the Covid sales will drive Pfizer’s earnings in 2022 to $5.71 a share.
Analysts surveyed by FactSet expect 2022 earnings at Pfizer of $5.47 a share.
It was announced last month that the U.S. government had agreed to buy 10 million treatment courses of Pfizer’s Paxlovid pill in a $5.29 billion deal.
Pfizer has asked the Food and Drug Administration to authorize the experimental pill. The pill reduced the risk of hospitalization among 1,219 high-risk patients by almost 90% in advanced clinical trials. The trial recorded no deaths among people who took the treatment.
Write to Joe Woelfel at firstname.lastname@example.org